Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: HSPA1B

Summary for HSPA1B

Gene information	Gene symbol	HSPA1B
	Ensembl ID	ENSG00000232804
	Entrez ID	3304
	Gene name	heat shock protein family A (Hsp70) member 1B
	Synonyms	HSP70-2
	Gene type	protein_coding
	UniProtAcc	P0DMV9

Top

Dataset with differentially expressed gene: HSPA1B

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-1.40853	2.00e-05
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.436248	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	1.34902	1.39e-36
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.895082	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.977643	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.942516	2.98e-10
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.737171	6.16e-42
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.546068	6.05e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	1.36682	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.829705	4.30e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.763118	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	1.07318	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.871511	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.428428	4.23e-19
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.976674	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.52955	2.80e-45
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	-0.555659	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	pDCs	-0.826419	3.18e-06
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	-0.651299	1.22e-18
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-1.25521	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.54126	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	-1.47494	3.10e-02
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.653794	5.80e-05
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-2.35287	3.16e-31
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	NK cells	-1.26464	3.30e-02
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-1.20208	1.50e-07
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-0.654173	2.32e-02
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.847201	3.22e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-1.39244	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	1.06419	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.657196	5.41e-13
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	B cells	-0.38837	1.35e-08
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	-0.940777	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD4+ T cells	-0.810682	8.97e-05
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-1.5534	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.499185	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.403832	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD4+ T cells	-0.516152	1.41e-14
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.640122	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	cDCs	-0.694851	2.10e-04
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.639128	0.00e+00

Top

Expression of HSPA1B in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to HSPA1B

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating HSPA1B

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
HSPA1B	hsa-miR-335-3p	95.8798	NM_005346
HSPA1B	hsa-miR-548p	91.9674	NM_005346
HSPA1B	hsa-miR-449a	90.7355	NM_005346
HSPA1B	hsa-miR-34a-5p	90.7355	NM_005346
HSPA1B	hsa-miR-449b-5p	88.5628	NM_005346
HSPA1B	hsa-miR-34c-5p	88.5628	NM_005346
HSPA1B	hsa-miR-520d-5p	85.5422	NM_005346
HSPA1B	hsa-miR-524-5p	85.5422	NM_005346
HSPA1B	hsa-miR-1283	85.4778	NM_005346
HSPA1B	hsa-miR-302c-5p	80.544	NM_005346

Page: 1

Top

Motifs and transcription factors (TFs) regulating HSPA1B

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
HSPA1B	transfac_pro__M06794	ZNF107 (directAnnotation).
HSPA1B	kznf__ZNF45_Imbeault2017_OM_RCADE	ZNF45 (directAnnotation).
HSPA1B	transfac_pro__M06402	ZNF493 (directAnnotation).
HSPA1B	metacluster_92.3	ZNF354A (directAnnotation). ZNF354B (inferredBy_Orthology).
HSPA1B	transfac_pro__M05688	ZNF133 (directAnnotation).
HSPA1B	taipale_tf_pairs__ERF_HES7_NCCGGAANNNNNNCACGYGNN_CAP_repr	ERF; HES7 (directAnnotation).
HSPA1B	dbtfbs__NCOA3_MCF-7_ENCSR573OJP_merged_N2	NCOA3 (directAnnotation).
HSPA1B	transfac_pro__M05976	ZNF223 (directAnnotation).
HSPA1B	cisbp__M01815	CEBPE (inferredBy_Orthology).
HSPA1B	transfac_pro__M00641	HSF1 (directAnnotation).
HSPA1B	transfac_pro__M06834	PEG3 (directAnnotation).
HSPA1B	transfac_pro__M06311	ZNF568 (directAnnotation).
HSPA1B	metacluster_22.13	MAFK (inferredBy_Orthology).
HSPA1B	cisbp__M02748	NFATC1 (directAnnotation).
HSPA1B	transfac_pro__M06872	ZNF671 (directAnnotation).
HSPA1B	transfac_pro__M06849	ZNF528 (directAnnotation).
HSPA1B	transfac_pro__M05991	ZFP64 (directAnnotation).
HSPA1B	transfac_pro__M06651	ZNF670 (directAnnotation).
HSPA1B	taipale_cyt_meth__DMRTC2_RAACGATACA_eDBD_repr	DMRTC2 (directAnnotation).
HSPA1B	metacluster_56.3	HSF2 (directAnnotation).
HSPA1B	transfac_pro__M06363	ZNF730 (directAnnotation).
HSPA1B	taipale_tf_pairs__MEIS1_DRGX_TGTCAATTA_CAP_repr	DRGX; MEIS1 (directAnnotation).
HSPA1B	dbtfbs__ZBTB26_HepG2_ENCSR184SVO_merged_N1	ZBTB26 (directAnnotation).
HSPA1B	taipale__ELK1_full_NACTTCCGSCGGAARMN_repr	ELK1 (directAnnotation).
HSPA1B	transfac_pro__M05964	ZNF48 (directAnnotation).
HSPA1B	transfac_pro__M06913	ZNF256 (directAnnotation).
HSPA1B	cisbp__M08190	ZEB1 (directAnnotation).
HSPA1B	metacluster_160.7	ZSCAN21 (directAnnotation).
HSPA1B	transfac_pro__M06173	ZNF85 (directAnnotation).
HSPA1B	transfac_pro__M06764	ZNF112 (directAnnotation).
HSPA1B	tfdimers__MD00411	ELF5; YY1 (directAnnotation).
HSPA1B	metacluster_130.2	ZNF182; ZNF22; ZNF225; ZNF225; ZNF285; ZNF362; ZNF362; ZNF384; ZNF487; ZNF512; ZNF570; ZNF613 (directAnnotation). ZNF384 (inferredBy_Orthology).
HSPA1B	metacluster_22.18	BACH2 (inferredBy_Orthology).
HSPA1B	metacluster_22.32	NFE2L2 (directAnnotation).
HSPA1B	metacluster_22.19	NFE2 (directAnnotation).
HSPA1B	transfac_pro__M05740	ZNF667 (directAnnotation).
HSPA1B	metacluster_22.15	BACH1 (directAnnotation).
HSPA1B	taipale_tf_pairs__POU2F1_ELK1_NCCGGATATGCAN_CAP_repr	ELK1; POU2F1 (directAnnotation).
HSPA1B	transfac_pro__M05682	ZNF25 (directAnnotation).
HSPA1B	metacluster_79.16	PRDM15; PRDM15 (inferredBy_Orthology).
HSPA1B	metacluster_65.19	HSF1 (directAnnotation).
HSPA1B	transfac_pro__M06741	ZNF70 (directAnnotation).
HSPA1B	metacluster_22.28	BACH1 (directAnnotation).
HSPA1B	metacluster_22.14	BACH1 (inferredBy_Orthology).
HSPA1B	metacluster_22.36	BACH2 (directAnnotation).
HSPA1B	transfac_pro__M06271	ZNF284 (directAnnotation).
HSPA1B	taipale_tf_pairs__HOXD12_TBX21_NGGTGTNNNNNNNNNNNNNCACNTNNTWAN_CAP_repr	HOXD12; TBX21 (directAnnotation).
HSPA1B	transfac_pro__M06037	ZNF197 (directAnnotation).
HSPA1B	taipale_tf_pairs__GCM2_SOX15_RTRCGGGNNNRNACAAWN_CAP_repr	GCM2; SOX15 (directAnnotation).
HSPA1B	transfac_pro__M06339	ZNF425 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."